Table 6

Tacrolimus: Vehicle-controlled trials 3 to 12 weeks in duration

Author, year
Quality
PopulationN (tacrolimus)N (total)Disease severityIntervention
Boguniewicz 199823
Fair
Children, 7 to 16 years0.03%: 43
0.1%: 49
180Moderate 73%–88%
Severe 12%–27%
Tacrolimus 0.03%, 0.1%, 0.3% ointment twice daily
Hanifin 200116 (study #35)
Fair
Adults, >16 years0.03%: 103
0.1%: 99
304Moderate 39%–52%
Severe 48%–61%
Tacrolimus 0.03%, 0.1% ointment twice daily
Hanifin 200116 (study #36)
Fair
Adults, >16 years0.03%: 108
0.1%: 110
328Moderate 36%–43%
Severe 56%–64%
Tacrolimus 0.03%, 0.1% ointment twice daily
Paller 200117
Fair
Children, 2 to 15 years0.03%: 117
0.1%: 118
351Moderate 36%–41%
Severe 60%–64%
Tacrolimus 0.03%, 0.1%, ointment twice daily
Ruzicka 199724
Fair
Children and adults, 13 to 60 years0.03%: 54
0.1%: 54
213Moderate to severe (% not reported)Tacrolimus 0.03%, 0.1%, 0.3% ointment twice daily
Schachner 200537
Fair
Children, 2 to 15 years0.03%: 158317Mild 60%
Moderate 40%
Tacrolimus 0.03% ointment twice daily

From: Results

Cover of Drug Class Review: Topical Calcineurin Inhibitors
Drug Class Review: Topical Calcineurin Inhibitors: Final Report [Internet].
Lee NJ, McDonagh M, Chan B, et al.
Portland (OR): Oregon Health & Science University; 2008 Oct.
Copyright © 2008, Oregon Health & Science University, Portland, Oregon.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.